British American Tobacco (BAT) London stock price rose 13.99% last week, from 4267 pence on May 8th to 4864 pence on May 15th. The background of market attention includes the recent authorization of Glas’s seasoning ENDS products by the US FDA, the rejection of BAT’s criminal case involving North Korea sanctions by a US court, and the company’s previously announced £ 1.3 billion stock repurchase plan. Analysts believe that although the FDA decision did not involve Vuse products under BAT, it changed some of the market’s expectations for the regulatory environment of flavored electronic cigarettes in the United States. At the same time, the growth of new nicotine products such as VELO continues to attract investors’ attention.
Key points of BAT stock price rising
- BAT London’s stock price rose 13.99% last week and closed at 4864 pence on May 15th.
- The recent authorization of Glas flavored ENDS products by the US FDA has raised market concerns about the evaluation environment for flavored vapes.
- BAT’s criminal case involving North Korea sanctions has been dismissed by a US court, and the company’s historical compliance risks have been temporarily alleviated.
- The company previously announced a £ 1.3 billion stock buyback plan for 2026, and new nicotine businesses such as VELO continue to attract investor attention.
According to market data cited by Bezkabli. pl, the London listed stock of British American Tobacco (BAT) rose 13.99% last week, from 4267 pence on May 8th to 4864 pence on May 15th.
Looking at it on a daily basis, BAT’s stock price rose 5.82% on May 12th, the largest daily increase of the week; On May 13th, it rose by 3.73%, and on May 14th, it rose by 3.22%. On May 15th, BAT’s stock price fell by 1.98%, indicating a certain level of profit taking in the market after continuous gains.
FDA authorization of Glas flavor vape products has attracted market attention
One of the backgrounds of the changing market sentiment is the recent authorization by the US Food and Drug Administration (FDA) for four flavored electronic nicotine delivery systems (ENDS) products under Glas. This authorization does not involve Vuse products under BAT, but it has attracted attention from investors in the tobacco and vape industries due to its involvement in flavored vape products.
For a long time, flavored vape products in the United States has faced high uncertainty in the pre-market tobacco product application (PMTA) review. This authorization is seen by the market as an important signal to observe the trend of US flavor vape product review. However, the FDA’s authorization target is Glas, and the relevant decision cannot be directly equated with a regulatory breakthrough for BAT products.
BAT’s criminal case involving North Korea sanctions rejected
In addition to regulatory background, BAT also obtained a company level legal progress last week. Reuters reported that a US judge has dismissed a criminal case against BAT for allegedly violating North Korean sanctions. The US Department of Justice stated that BAT has fully complied with its 2023 deferred prosecution agreement.
According to the previous agreement, BAT agreed to pay approximately $630 million in fines and unpaid payments, and strengthen relevant compliance procedures. After the case was dismissed, the market’s concerns about BAT’s historical legal and compliance risks have eased.
Repurchase plan and new nicotine business receive attention
BAT previously announced that it will implement a stock buyback plan of up to £ 1.3 billion by 2026. For investors, the repurchase plan demonstrates that the company still has stable cash flow and capital return capabilities.
Meanwhile, BAT’s new nicotine product business continues to receive attention. Vuse, a subsidiary of the company, is one of the major vape brands in the US market, while VELO competes with brands such as ZYN under Philip Morris International (PMI) in the oral nicotine market. The market is concerned about whether BAT’s new nicotine business can continue to expand its growth space in the context of changes in the regulatory environment and intensified competition for compliant products in the United States.
The rise reflects the improvement of regulatory expectations, but it does not mean that the results will be implemented
From an industry perspective, the rise in BAT’s stock price last week reflects the capital market’s expectations for changes in the regulatory environment for new nicotine products in the United States. FDA authorizes Glas flavored ENDS products, refocusing investors’ attention on the possibility of flavored vapes being authorized under the PMTA pathway; The BAT legal risk mitigation and repurchase plan have strengthened the support at the company level.
However, this round of rise should still be interpreted with caution. The FDA authorization target is not BAT products, and there are still public health controversies and policy uncertainties in the regulation of flavored vapes in the United States. For BAT, the long-term growth of Vuse and VELO still depends on the US regulatory path, market competition, and whether compliant products can continue to gain consumer acceptance.
Reference: BAT stock up 14% this week, Monday in focus
Something about BAT vape
A few years ago, when I was working at JSBvape. We had a refillable vape pod system called Erino that was getting a lot of attention in the UK.
We promoted that product and got the attentions from BAT and VPZ in UK. That was my former employer, a Chinese vape manufacturer. BAT gave us a very high rating. And We sent a several samples to them for testing.
0 Comments